Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation.
10.3760/cma.j.issn.0253-2727.2018.05.007
- Author:
Zhi Tao YING
1
;
Lan MI
;
Xue Juan WANG
;
Yue Wei ZHANG
;
Zhi YANG
;
Yu Qin SONG
;
Xiao Pei WANG
;
Wen ZHENG
;
Ning Jing LIN
;
Mei Feng TU
;
Yan XIE
;
Ling Yan PING
;
Chen ZHANG
;
Wei Ping LIU
;
Li Juan DENG
;
Jun ZHU
Author Information
1. Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Publication Type:Journal Article
- Keywords:
Fluorodeoxyglucose F18;
Hematopoietic stem cell transplantation;
Lymphoma, large B-cell, diffuse;
Positron-emission tomography and computed tomography
- MeSH:
Adolescent;
Adult;
Disease-Free Survival;
Female;
Fluorodeoxyglucose F18;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Male;
Middle Aged;
Positron Emission Tomography Computed Tomography;
Prognosis;
Retrospective Studies;
Transplantation, Autologous;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(5):382-386
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the prognostic value of (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in patients with diffuse large B cell lymphoma (DLBCL) undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). Methods: Forty-eight patients with DLBCL treated at Peking University Cancer Hospital between November 2010 and December 2014 were assessed. All patients underwent PET/CT scanning prior to or after auto-HSCT. Correlation analysis was done based upon patients characteristics, PET/CT scan results and survival. Results: ①Among 48 patients, 27 was male, 21 female, median age was 43 (17-59) years old. ② Patients with negative pre-auto-HSCT PET/CT assessment demonstrated significantly better 3-year progression free survival (PFS) (87.1% vs 53.3%, χ(2)=7.02, P=0.019) and overall survival (OS) (90.3% vs 60.0%, χ(2)=6.51,P=0.022) than patients with positive pre-auto-HSCT PET/CT assessment. Three-year PFS (94.1% vs 30.0%, χ(2)=22.75, P=0.001) and OS (97.1% vs 40.0%, χ(2)=21.09, P=0.002) were also significantly different between patients with negative and positive post-auto-HSCT PET/CT assessment. ③ Multivariate analysis indicated a significant association of PFS (HR=13.176, P=0.005) and OS (HR=20.221, P=0.007) with post-auto-HSCT PET/CT assessment. Number of prior treatment regimens was associated with PFS (HR=10.039, P=0.040). ④ Harrell's C index revealed that the value of combined use of number of prior treatment regimens and post-auto-HSCT PET/CT assessment was superior to either one used alone in PFS (Harrell's C values were 0.976, 0.869 and 0.927 in combined use, number of prior treatment regimens and post-auto-HSCT PET/CT assessment, respectively), and the combined use of ECOG performance status and post-auto-HSCT PET/CT assessment significantly increased the Harrell's C index in OS (Harrell's C values were 0.973, 0.711 and 0.919 in combined use, ECOG performance status and post-auto-HSCT PET/CT assessment, respectively). Conclusions: Post-auto-HSCT PET/CT assessment is the main predictor of outcomes in DLBCL patients receiving auto-HSCT. Combined use of post-auto-HSCT PET/CT assessment and number of prior treatment regimens and ECOG performance status is a better prognostic tool in patients with DLBCL undergoing transplantation.
